Biological medication for rheuma

No definition available.

Endpoint definition

FinnGen phenotype data
diagram bullet diagram downward connector

Filter registries KELA purch., KELA reimb.

Medicine purchases: ATC L04AA24|L04AC03|L04AB04|L04AB01|L04AB06|L04AB02|L04AB05|L04AA26|L01XC02|L04AC10|L04AC07|L04AC05
Medicine purchases: ATC: other data required >3 instances required

Check pre-conditions None

Include endpoints None

Check conditions None

Apply sex-specific rule None

diagram downward connector RX_RHEUMA_BIOLOGICAL

Extra metadata

First used in FinnGen datafreeze DF5

Summary Statistics

Key figures

All Female Male
Number of individuals 2648 1615 1033
Unadjusted prevalence (%) 1.02 1.10 0.91
Mean age at first event (years) 47.02 46.84 47.32

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.07 4.78 [2.85, 8.02] 3.1e-9 29
15 years 0.03 4.78 [2.85, 8.02] 3.1e-9 29
5 years 0.00 4.29 [2.25, 8.17] 9.3e-6 13
1 year - - - -

Correlations

Index endpoint: RX_RHEUMA_BIOLOGICAL – Biological medication for rheuma
GWS hits: 10

Survival analyses between endpoints

Plot

before Biological medication for rheuma
after Biological medication for rheuma

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Biological medication for rheuma